Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.35 |
| ▸ | MAPT | P10636 | 6/20 | 0.34 |
| ▸ | NPC1 | O15118 | 3/20 | 0.33 |
| ▸ | RAB9A | P51151 | 3/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 4/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | HTT | P42858 | 2/20 | 0.32 |
| ▸ | MITF | O75030 | 1/20 | 0.32 |
| ▸ | CCR6 | P51684 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27939756 | 0.90 | KMT2A (0.39) | MEN1KMT2AALDH1A1MAPTNPC1 | |
| SCHEMBL6543834 | 0.88 | NR1H4 (0.35) | MEN1KMT2AALDH1A1MAPTNPC1 | |
| SCHEMBL27782510 | 0.87 | RAB9A (0.33) | MEN1KMT2AALDH1A1MAPTNPC1 | |
| SCHEMBL3487495 | 0.87 | ALDH1A1 (0.41) | MEN1KMT2AALDH1A1MAPTNPC1 | |
| SCHEMBL3487106 | 0.86 | HSD17B1 (0.44) | MEN1KMT2AALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL3243692 | 0.86 | ALDH1A1 (0.34) | ALDH1A1MAPTNPC1RAB9ALMNA | |
| SCHEMBL27782480 | 0.85 | ABL1 (0.34) | MEN1KMT2AALDH1A1MAPTNPC1 | |
| SCHEMBL4450704 | 0.85 | ALDH1A1 (0.48) | MEN1KMT2AALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL6544430 | 0.84 | MMP13 (0.42) | ALDH1A1SMN1; SMN2KDM4ENPSR1 | |
| SCHEMBL6543570 | 0.84 | MERTK (0.40) | MEN1KMT2AALDH1A1MAPTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130183297-A1 | METHOD OF TREATING CANCERS AND A PHARMACEUTICAL COMPOSITION THAT MAY BE USED IN PRACTICING SAID METHOD | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-07-18 | — | — | US | disclosed |
| US-20130165446-A1 | BENZO-OR PYRIDO-IMIDAZOLE DERIVATIVE | HORIKOSHI, HIROYOSHI (CA) | 2013-06-27 | — | — | US | disclosed |
| EP-2581373-A1 | BENZO- OR PYRIDO-IMIDAZOLE DERIVATIVE | Fujita, Takashi (JP) | 2013-04-17 | — | — | EP | disclosed |
| US-20120263716-A1 | METHOD OF TREATING CANCERS AND A PHARMACEUTICAL COMPOSITION THAT MAY BE USED IN PRACTICING SAID METHOD | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-10-18 | — | — | US | disclosed |
| US-20120258991-A1 | METHOD OF TREATING A CANCER BY ADMINISTERING A SPECIFIED DRUG | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-10-11 | — | — | US | disclosed |
| US-8263631-B2 | Anti-cancer pharmaceutical compositions and methods for treating patients with cancer | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-09-11 | — | — | US | disclosed |
| EP-1167366-B1 | AMINE DERIVATIVES | DAIICHI SANKYO CO LTD (JP) | 2010-05-05 | — | — | EP | disclosed |
| US-20090028868-A1 | Anti-cancer pharmaceutical compositions and methods for treating patients with cancer | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-01-29 | — | — | US | disclosed |
| EP-1982718-A1 | ANTI-CANCER PHARMACEUTICAL COMPOSITION | Daiichi Sankyo Company, Limited (JP) | 2008-10-22 | — | — | EP | disclosed |
| CN-1162427-C | Amine derivatives compounds | ������������ʽ���� | 2004-08-18 | — | — | CN | disclosed |
| US-20040002512-A1 | Alpha-substituted carboxylic acid derivatives | SANKYO COMPANY, LIMITED (JP) | 2004-01-01 | — | — | US | disclosed |
| US-6596751-B2 | An insulin resistance improving agent, hypoglycemic agent, immunoregulatory agent, aldose reductase inhibitor, 5-lipoxygenase inhibitor, peroxidized lipid production suppressor, PPAR. activator, leukotriene antagonist, adipose | SANKYO COMPANY LIMITED (JP) | 2003-07-22 | — | — | US | disclosed |
| US-6562849-B1 | Amine compound or pharmacologically acceptable salt thereof. These compounds are useful in the treatment and/or prophylaxis of diseases such as diabetes, hyperlipemia, arteriosclerosis, cancer, etc. | SANKYO COMPANY, LIMITED (JP) | 2003-05-13 | — | — | US | disclosed |
| US-20030078426-A1 | Amine derivative compounds | SANKYO COMPANY, LIMITED (JP) | 2003-04-24 | — | — | US | disclosed |
| US-20030069294-A1 | Alpha-substituted carboxylic acid derivatives | SANKYO COMPANY, LIMITED (JP) | 2003-04-10 | — | — | US | disclosed |
| US-6432993-B1 | BENZIMIDAZOLE OR IMIDAZO(4,5-B)PYRIDINE DERIVATES; IMMUNOMODULATORS; ALDOSE REDUCTASE AND LIPOXYGENASE INHIBITORS; DIABETES; PREVENTS LIPID PEROXIDATION; ANTILIPEMIC, HYPOTENSIVE AGENTS | SANKYO COMPANY, LIMITED (JP) | 2002-08-13 | — | — | US | disclosed |
| CN-1354750-A | Amine derivatives compounds | SANKYO CO (JP) | 2002-06-19 | — | — | CN | disclosed |
| EP-1167357-A1 | ALPHA-SUBSTITUTED CARBOXYLIC ACID DERIVATIVES | Sankyo Company, Limited (JP) | 2002-01-02 | — | — | EP | disclosed |
| EP-1167366-A1 | AMINE DERIVATIVES | Sankyo Company, Limited (JP) | 2002-01-02 | — | — | EP | disclosed |
| EP-1022272-A1 | SUBSTITUTED FUSED HETEROCYCLIC COMPOUNDS | Sankyo Company Limited (JP) | 2000-07-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040002512-A1 | Alpha-substituted carboxylic acid derivatives | SLC5A1, SLC2A1, GPR119 | MEN1 3577/4885KMT2A 1979/4885ALDH1A1 28/4885 |
| US-20120258991-A1 | METHOD OF TREATING A CANCER BY ADMINISTERING A SPECIFIED DRUG | RNASE1, MCL1, EWSR1 | MEN1 104/4885KMT2A 55/4885ALDH1A1 131/4885 |
| US-20120263716-A1 | METHOD OF TREATING CANCERS AND A PHARMACEUTICAL COMPOSITION THAT MAY BE USED IN PRACTICING SAID METHOD | EGFR, ABL1, ERBB2 | MEN1 2692/4885KMT2A 784/4885ALDH1A1 709/4885 |
| US-20030069294-A1 | Alpha-substituted carboxylic acid derivatives | SLC5A1, SLC2A1, GPR119 | MEN1 3577/4885KMT2A 1979/4885ALDH1A1 28/4885 |
| US-20090028868-A1 | Anti-cancer pharmaceutical compositions and methods for treating patients with cancer | EGFR, ERBB2, KDR | MEN1 645/4885KMT2A 2218/4885ALDH1A1 2596/4885 |
| US-20030078426-A1 | Amine derivative compounds | H1-10, APOB, PRMT1 | MEN1 300/4885KMT2A 85/4885ALDH1A1 874/4885 |
| US-20130183297-A1 | METHOD OF TREATING CANCERS AND A PHARMACEUTICAL COMPOSITION THAT MAY BE USED IN PRACTICING SAID METHOD | EGFR, ABL1, ERBB2 | MEN1 2692/4885KMT2A 784/4885ALDH1A1 709/4885 |
| US-20130165446-A1 | BENZO-OR PYRIDO-IMIDAZOLE DERIVATIVE | PPARG, PPARA, PPARD | MEN1 4822/4885KMT2A 1996/4885ALDH1A1 1612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.